Market Intelligence, Clinical Progress, and High-Purity Reagents for Hypoxia-Induced Pulmonary Hypertension, Neurological Disorders, and Zinc-Dependent Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SLC39A12 drug discovery, covering both membrane protein tools and selectivity profiling panels.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SLC39A12 ECD-Fc / Mutant Protein; High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. | View SLC39A12 Products |
| Gene Delivery | SLC39A12 Lentivirus Particles ( >10^8 TU/ml); Full-length ORF for stable membrane protein expression in mammalian cells. Preserves native N-glycosylation. Sequence Verified. | View SLC39A12 Products |
| Gene ORF | SLC39A12 Promise-ORF Clone; Native sequence verified by NGS, ready for transfection. | View SLC39A12 Products |
| Benchmark Antibody | Anti-SLC39A12 (Reference Sequence); Recombinant positive control for assay benchmarking. | View SLC39A12 Products |
| RNAi Validator | SLC39A12 siRNA Set (3 unique targets); For knockdown verification and specificity controls in functional assays. | View SLC39A12 Products |
| Related Target A | BMPR2; Key receptor in pulmonary arterial hypertension pathogenesis, relevant for co-targeting strategies. | View BMPR2 Products |
| Related Target B | HIF1A; Master regulator of hypoxia, upstream driver of SLC39A12 expression. | View HIF1A Products |
| Related Target C | SLC39A1 (ZIP1); Compensatory zinc importer in SLC39 family, critical for selectivity profiling. | View SLC39A1 Products |
| Related Target D | SLC30A1 (ZnT1); Zinc efflux transporter, functional antagonist for zinc homeostasis studies. | View SLC30A1 Products |
| Related Target E | SLC39A6 (ZIP6); Zinc transporter involved in metastasis, paralog for off-target screening. | View SLC39A6 Products |
Key Assay Challenges & TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Membrane Conformation / 8-TM Topology & Native Glycosylation | HEK293-expressed Lentivirus preserves native N-glycosylation (Asn-X-Ser/Thr motifs) critical for proper trafficking and membrane insertion. Enables stable cell line construction for zinc flux assays. |
| Subfamily Off-target Screening / Selectivity (ZIP vs ZnT) | Ortholog panel including SLC39A1, SLC39A6, SLC30A1 lentiviral particles available for counter-screening. Target-specific regions sequence-verified to ensure specificity against other ZIP family transporters (e.g., ZIP8, ZIP14). |
| Zinc Flux Quantification | Stable cell line generation supported; compatible with FluoZin-3 and radioactive 65Zn uptake assays. |
| Lack of Controls / Specificity Validation | Sequence Verified Reference Antibodies and target-specific siRNA sets included for reliable assay benchmarking and knockdown verification. |
| False Positives in Screening | Validated siRNA included for specificity checks and target validation in phenotypic models. |
Live SLC39A12 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
SLC39A12 (ZIP12) is an emerging therapeutic target investigated across multiple disease areas including hypoxia-induced pulmonary hypertension, neurological conditions (schizophrenia, ALS, cognitive disorders), and zinc-dependent oncology (prostate cancer, breast cancer). As a multi-pass membrane zinc transporter with eight transmembrane domains (8-TM) and N-glycosylation sites, traditional biologics face significant challenges. Consequently, the research landscape is heavily skewed toward small molecule inhibitors, allosteric modulators, and advanced gene silencing techniques (siRNA/ASO). Current R&D primarily involves academic consortia, early biotech, and neuroscience drug discovery teams. Future R&D is expected to focus on optimizing cell-based screening assays to identify selective ZIP12 inhibitors and BBB-penetrant allosteric modulators that do not cross-react with other essential zinc transporters (e.g., ZIP8, ZIP14). In oncology, combination strategies with zinc ionophores and co-expression models with SLC30A1 (ZnT1) are gaining interest.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Academic Consortia, Early Biotech | Pulmonary Hypertension, Schizophrenia, ALS | Cell-based zinc uptake assay (Requires stable expression via Lentivirus) |
| Allosteric Modulator | Neuroscience Drug Discovery | Cognitive Disorders | Conformational ELISA using full-length membrane protein |
| siRNA / Antisense Oligonucleotide | Preclinical Discovery, Rare Disease Focus | Neurological Disorders, ZIP12 Overexpression Cancers | Knockdown Validation (Need High-specificity siRNA) |
| Monoclonal Antibody | Preclinical Discovery | Hypoxia Models | Extracellular Loop Binding (Need sequence-verified antigens) |
| Zinc Ionophore Combination | Oncology Biotech | Prostate Cancer, Breast Cancer | Cross-talk studies with SLC30A1 (ZnT1) co-expression models |
Key Genetic Variants
Known single nucleotide polymorphisms in SLC39A12 with potential functional impact include:
| dbSNP ID | Variant Evidence (UniProt) |
|---|---|
| rs10764176 | VAR_037516 |
| rs7899328 | VAR_037517 |
| rs2478568 | VAR_037518 |
This information is derived from UniProt entry Q504Y0.